6 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Terminated 3, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Terminated 2, Active not recruiting 1 |
Follow LY2940680: new trials by email Literature Review of LY2940680 trials Research Report on LY2940680
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants taladegib, nintedanib, pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Recruiting | Endeavor Biomedicines, Inc. | 57 | 2026-04-28 | 2026-05-15 |
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Active not recruiting | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-02-24 |
| A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects taladegib, nintedanib - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Endeavor Biomedicines, Inc. | 21 | 2023-05-03 | 2023-12-15 |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 20 | 2022-05-24 | 2026-03-05 |
| A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) taladegib, placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 41 | 2021-08-26 | 2024-12-02 |
| Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis - Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2017-03-07 | 2023-07-10 |
| A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors LY3039478, Taladegib, Abemaciclib - Solid Tumor, Breast Cancer | Phase 1 | Terminated | Eli Lilly and Company | 94 | 2016-11-04 | 2025-08-21 |
| A Study of LY2940680 in Japanese Participants With Advanced Cancers LY2940680 - Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 19 | 2013-08-01 | 2019-09-11 |
| A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma LY2940680 - Medulloblastoma, Childhood, Rhabdomyosarcoma | Phase 1 | Withdrawn | Eli Lilly and Company | 2013-07-01 | 2013-08-27 | |
| A Study of LY2940680 in Small Cell Lung Cancer LY2940680, Carboplatin, Etoposide - Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 26 | 2013-01-01 | 2018-12-28 |
| A Study of LY2940680 in Healthy Participants LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole - Healthy Participants | Phase 1 | Completed | Eli Lilly and Company | 30 | 2012-09-01 | 2019-10-21 |
| A Study in Advanced Cancer Taladegib - Advanced Cancer | Phase 1 | Completed | Eli Lilly and Company | 84 | 2010-09-01 | 2019-09-13 |
Idiopathic Pulmonary Fibrosis (4) · Pulmonary Fibrosis (3) · Medulloblastoma (2) · Neoplasm Metastasis (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Adenocarcinoma Of Esophagus (1) · Adenoma, Islet Cell (1) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Glioma (1) · Laryngeal Diseases (1) · Melanoma (1) · Mesothelioma (1)
Eli Lilly and Company (6) · Endeavor Biomedicines, Inc. (5) · M.D. Anderson Cancer Center (1)
United States (7) · Australia (4) · Canada (2) · France (2) · Malaysia (2) · Mexico (2) · South Korea (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Denmark (1) · Germany (1) · Ireland (1) · Italy (1)
Lisa Lancaster, M.D. (3) · Jaffer A Ajani (1) · John Huetsch, M.D. (1) · Paul Frohna, M.D., Ph.D. (1)
PMID 33686452, PMID 36030462, PMID 41043447
2015 (1)